D’Agostino, Claudia
Filipovic, Nikola
Zindy, Egor
Conrard, Louise
Wang, Zhen
Moscato, Stefania
Engelke, Fiona
Nash, Angelica
Hagströmer, Carl Johan
Strandberg, Helin
Parisis, Dorian
Datlibagi, Azine
Gregoire, Françoise
Bolaky, Nargis
Tarabichi, Maxime
Soyfoo, Muhammad Shahnawaz
Schey, Kevin L.
Dörner, Thomas
Witte, Torsten
Perret, Jason
Mattii, Letizia
Törnroth-Horsefield, Susanna
Delporte, Christine
Funding for this research was provided by:
European Regional Development Fund and the Walloon Region (Wallonia-Biomed; project “CMMI-ULB”, Wallonia-Biomed; project “CMMI-ULB”)
Fonds De La Recherche Scientifique - FNRS (PINT-BILAT-P-R.P006.19)
Fonds Erasme pour la recherche médicale
National Institutes of Health (EY013462)
Deutsche Forschungsgemeinschaft (Germany’s Excellence Strategy – EXC 2155 – project number 390874280)
Swedish Research Council Röntgen-Ångström (2017-06727 and 2019-06106)
Fondation Jaumotte-Demoulin
Fonds Octave Dupont from the Royal Academy of Belgium
Article History
Received: 22 April 2025
Accepted: 4 October 2025
First Online: 3 November 2025
Declarations
:
: Mouse salivary glands were obtained from C57Bl6 mice (Janvier-Labs, Le Genest-Saint-Isle, France) with all animal care and experiments approved by the local Animal and Welfare Committee (Protocol 489 N) and carried out in agreement with the local and national guidelines. The study on hMSGB was approved by the ULB Erasme Hospital ethics committee (P2020/351), with no patients opposing to the use of the human residual clinical material for research purposes, and no need for informed consent in compliance with Belgian law. The autoantibody study was approved by the local ethics committee (Vote Hannover Medical School ethical committee No. 5582; Berlin ethical committee agreement EA1/002/16; Udine ethical committee agreement CEUR-2017-Os-027-ASUIUD)
: The use the human residual clinical material for research purposes does not require informed consent in compliance with Belgian law.
: The authors declare no competing interests.